[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627489":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":26,"responsibleParty":42,"collaborators":26,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"University of Utah","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral LNG + Piroxicam","EXPERIMENTAL","Compare EC efficacy among 1,458 U.S. participants randomly assigned 3:1 to oral LNG + piroxicam vs. oral LNG + placebo. This ARM will provide participants Oral LNG plus Piroxicam.",[13],"Drug: Levonorgestrel 1.5 mg and Piroxicam 40 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Oral LNG + Placebo","PLACEBO_COMPARATOR","Compare EC efficacy among 1,458 U.S. participants randomly assigned 3:1 to oral LNG + piroxicam vs. oral LNG + placebo. This Arm will assign participants to oral lng plus a placebo.",[19],"Drug: Oral LNG + Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Levonorgestrel 1.5 mg and Piroxicam 40 mg","The study intervention is a combination of Levonorgestrel 1.5 mg and Piroxicam 40 mg for emergency contraception. Participants will be randomized 3:1 to this vs. Levonorgestrel 1.5 mg and placebo.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"The study intervention is a combination of Levonorgestrel 1.5 mg and placebo for emergency contraception. Participants will be randomized 3:1 to Levonorgestrel 1.5 mg and Piroxicam vs. this option.",[15],[31],{"name":32,"affiliation":5,"role":33},"David Turok, MD, MPH","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","801-213-2995","david.turok@hsc.utah.edu",{"name":40,"role":36,"phone":37,"phoneExt":26,"email":41},"Sarah DeLuca, MPH","sarah.deluca@hsc.utah.edu",{"type":43,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100627489","phase-3-rct-assessing-pregnancy---piroxicam-for-ec-with-levonorgestrel-100627489",false,"NCT07449299","Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","RAPPEL","Inclusion Criteria:\n\n* Between 16-35 years old and desire LNG for EC\n* Unprotected intercourse within 72 hours\n* Biologically capable of pregnancy\n* Regular menstrual cycle 21-35 days long with known LMP +\u002F- 3 days\n* Working cell phone number that receives text messages (for Aim 3 participants phone with capability to download and use the Oova application and submit data)\n* Fluent in English and\u002For Spanish\n* Willing to comply with the study requirements including 1-month urine pregnancy test\n* No known contraindications to oral LNG or piroxicam - For secondary outcome assessing pregnancy risk for participants receiving study drug on day of ovulation or later - are currently using a menstrual cycle tracking application and can demonstrate according to the application that they are on the day of ovulation or post ovulation.\n\nExclusion Criteria:\n\n* Current pregnancy (+urine pregnancy test in clinic)\n\n  * Breastfeeding, post abortion or postpartum without resuming menstruation\n  * Use of hormonal contraception (including oral EC) within seven days of enrollment\n  * Use of NSAIDs (ibuprofen, naproxen, celecoxib, diclofenac, aspirin) in the prior week\n  * Highly effective contraception including permanent contraception (including partner with vasectomy), IUD, or contraceptive implant\n  * Allergy to LNG or piroxicam\n  * Desires UPA for EC\n\nHistory of stroke, myocardia infarction, ischemic heart disease, uncontrolled hypertension, congestive heart failure, peptic ulcer disease, renal or hepatic failure. Currently taking anticoagulants, corticosteroids, cyclosporine, lithium, methotrexate, or tacrolimus.","FEMALE","16 Years","35 Years",{"count":55,"type":56},1458,"ESTIMATED","INTERVENTIONAL",[59],"PHASE3","This randomized controlled trial will test oral levonorgestrel + piroxicam vs. levonorgestrel + placebo for emergency contraception in a representative U.S. population that has higher pregnancy risk than in the prior study because of higher weights, different intercourse patterns, and different clinic accessibility. Data from this project will inform clinical practice in the U.S. and beyond for those desiring the most effective method of emergency contraception pills.",[62,63,64],"Emergency Contraception","Contraception","COX-2 Inhibitor",[62,66,63],"Piroxicam","NOT_YET_RECRUITING","2026-02-26",{"date":70,"type":71},"2026-03-04","ACTUAL",{"date":73,"type":56},"2027-03",{"date":75,"type":56},"2031-11",{"name":5,"class":6}]